How could non-vitamin k antagonist oral anticoagulants change clinical practice for stroke prevention and improve outcomes in patients with newly-diagnosed atrial fibrillation?
Four targeted therapies and less than four targeted therapies of underlying conditions against conventional therapy in atrial fibrillation - data from the RACE 3 study
High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI